Servier Links Up With Celladon For Potential Diabetes Drugs
This article was originally published in The Pink Sheet Daily
Servier inks its second deal in less than two weeks, this time for potential diabetes candidates. While both deals are early, they mark the French biotech’s foray into two hot fields of research.
You may also be interested in...
Novartis beefs up its immunotherapy pipeline, while French biotech Servier makes a play to get in the CART game. Yet, the deal on everybody’s lips is Actavis’ acquisition of Forest. Plus news on Gilead and Pfizer.
The Anglo/Swiss pharma will work with University of Pennsylvania researchers to discover, develop and commercialize CAR immunotherapy drugs for cancer, while also establishing a joint R&D facility at the Philadelphia campus.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.